Australian biopharma company MindBio Therapeutics Corp. has shared positive topline results from its completed take-home microdosing clinical trial on major depressive disorder. The treatment provided to the 20 participants is MB22001, the company’s microdose formulation of a self-titratable form of LSD, adapted for use outside clinical settings and enabling patients to dose up or down depending on personal tolerance. Announced in May 2023 after positive Phase 1 trial results, the Phase 2a study’s positive outcomes stand as “transformative” for MindBio, now moving toward late-stage pharma drug…